Spanish healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a manufacturer of plasma-derived medicines, announced on Tuesday that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop a treatment for sulfur mustard-induced eye injury.
The treatment uses ocular surface immunoglobulin (OSIG) eye drops to neutralize symptoms caused by the chemical warfare agent.
If successful, the preclinical study could lead to US Food and Drug Administration (FDA) approval for the first medical treatment for sulfur mustard ocular injury.
Grifols is also developing an OSIG treatment for dry eye disease, which is expected to enter clinical trials in 2025.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study